Terms: = Lung cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
166 results:
1. Prognostic Model for High-Grade Neuroendocrine Carcinoma of the lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression.
Kim HS; Kim JK; Lee JH; Lee YJ; Lee GK; Han JY
JCO Precis Oncol; 2024 Apr; 8():e2300495. PubMed ID: 38635931
[TBL] [Abstract] [Full Text] [Related]
2. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract] [Full Text] [Related]
3. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Roskoski R
Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
[TBL] [Abstract] [Full Text] [Related]
4. A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma.
Li X; Xu C; Min Y; Zhai Z; Zhu Y
Clin Respir J; 2023 Dec; 17(12):1349-1360. PubMed ID: 38071755
[TBL] [Abstract] [Full Text] [Related]
5. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across cancer Types.
Kasi PM; Lee JK; Pasquina LW; Decker B; Vanden Borre P; Pavlick DC; Allen JM; Parachoniak C; Quintanilha JCF; Graf RP; Schrock AB; Oxnard GR; Lovly CM; Tukachinsky H; Subbiah V
Clin Cancer Res; 2024 Feb; 30(4):836-848. PubMed ID: 38060240
[TBL] [Abstract] [Full Text] [Related]
6. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
7. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
8. Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell lung cancer.
Ilnytskyy Y; Petersen L; McIntyre JB; Konno M; D'Silva A; Dean M; Elegbede A; Golubov A; Kovalchuk O; Kovalchuk I; Bebb G
Cancer Genomics Proteomics; 2023; 20(5):417-432. PubMed ID: 37643782
[TBL] [Abstract] [Full Text] [Related]
9. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.
Liang WW; Lu RJ; Jayasinghe RG; Foltz SM; Porta-Pardo E; Geffen Y; Wendl MC; Lazcano R; Kolodziejczak I; Song Y; Govindan A; Demicco EG; Li X; Li Y; Sethuraman S; Payne SH; Fenyö D; Rodriguez H; Wiznerowicz M; Shen H; Mani DR; Rodland KD; Lazar AJ; Robles AI; Ding L;
Cancer Cell; 2023 Sep; 41(9):1567-1585.e7. PubMed ID: 37582362
[TBL] [Abstract] [Full Text] [Related]
10. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
11. Detection of Nine Oncogenes Amplification in lung and Colorectal cancer Formalin-Fixed Paraffin-Embedded Tissue Samples using Combined Next-Generation Sequencing-Based Script and Digital Droplet Polymerase Chain Reaction.
Bontoux C; Guyard A; Lupo A; Diallo K; Rebah K; Hercent A; Guenzi E; Cros J; Lamoril J; Leroy K; Theou-Anton N
Cancer Control; 2023; 30():10732748231167257. PubMed ID: 37386758
[TBL] [Abstract] [Full Text] [Related]
12. Static Respiratory System Compliance as a Predictor of Extubation Failure in Patients with Acute Respiratory Failure.
Abplanalp LA; Ionescu F; Calvo-Ayala E; Yu L; Nair GB
Lung; 2023 Jun; 201(3):309-314. PubMed ID: 37300706
[TBL] [Abstract] [Full Text] [Related]
13. Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
El Shemerly M; Zanini E; Lecoultre M; Walker PR; Kellenberger L; Lane HA; McSheehy PMJ
Anticancer Drugs; 2023 Oct; 34(9):1035-1045. PubMed ID: 36729099
[TBL] [Abstract] [Full Text] [Related]
14. lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
15. Futibatinib: First Approval.
Syed YY
Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
[TBL] [Abstract] [Full Text] [Related]
16. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
Lai X; Yu R; Ou Q; Bao H; Wu X; Shao Y; Li Y; Zhang Y; Ding Q
Cancer Med; 2023 Mar; 12(5):6009-6015. PubMed ID: 36325957
[TBL] [Abstract] [Full Text] [Related]
17. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung KL; Luebeck J; Dehkordi SR; Colón CI; Li R; Wong IT; Coruh C; Dharanipragada P; Lomeli SH; Weiser NE; Moriceau G; Zhang X; Bailey C; Houlahan KE; Yang W; González RC; Swanton C; Curtis C; Jamal-Hanjani M; Henssen AG; Law JA; Greenleaf WJ; Lo RS; Mischel PS; Bafna V; Chang HY
Nat Genet; 2022 Nov; 54(11):1746-1754. PubMed ID: 36253572
[TBL] [Abstract] [Full Text] [Related]
18. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell lung cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract] [Full Text] [Related]
19. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
20. Genomic architecture of fgfr2 fusions in cholangiocarcinoma and its implication for molecular testing.
Neumann O; Burn TC; Allgäuer M; Ball M; Kirchner M; Albrecht T; Volckmar AL; Beck S; Endris V; Goldschmid H; Lehmann U; Seker-Cin H; Uhrig S; Roessler S; Budczies J; Fröhling S; Longerich T; Wagner AH; Vogel A; Schirmacher P; Stenzinger A; Kazdal D
Br J Cancer; 2022 Nov; 127(8):1540-1549. PubMed ID: 35871236
[TBL] [Abstract] [Full Text] [Related]
[Next]
